A ninth class action has been filed on behalf of junior doctors in Victoria who were allegedly underpaid for shift work, after two landmark wins in the Gordon Legal-led underpayments class actions.
Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.
The Commonwealth has argued that a long-running dispute involving drug makers Otsuka, Bristol-Myers Squibb and Generic Health should be put on ice until the High Court rules in a separate matter.
Medibank is seeking to shield from a shareholder class action an “irrelevant” post-incident report by Deloitte into its massive October 2022 data breach.
AstraZeneca has brought court proceedings to block Australian drug maker Pharmacor from making a generic version of its heart attack drug Brilinta.
Bayer has lost its battle to protect top-selling blood thinner Xarelto from generic competition, with the Full Court finding two patents for the drug are invalid.
The funder and law firm that ran a shareholder class action against Mayne Pharma are seeking deductions that would leave more than half of a $38 million settlement for group members.
Novartis unit Sandoz is appealing a tribunal decision in favour of pharmaceutical company Lundbeck over a licence to sell a generic version of leading antidepressant Lexapro.
Australian Clinical Labs, which is facing regulatory action over a 2022 data breach, is fighting the information commissioner’s claim that it breached privacy laws 21.5 million times.
IP Australia has rejected AFT Pharmaceuticals’ bid to patent a combination cold and flu medication, finding the invention was little more than putting three different medications “in a box”.